Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - Accuray reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of$ 0.05, and an improvement from a loss of $0.06 per share a year ago, representing an earnings surprise of 80% [1] - The company posted revenues of$ 113.24 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 10.86%, and up from $101.13 million in the same quarter last year [2] - Over the last four quarters, Accuray has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Outlook - Accuray shares have declined approximately 18.2% since the beginning of the year, compared to a decline of 5.5% in the S&P 500 [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at$ 0.08 on revenues of $149.95 million, and$ 0.01 on revenues of $469.8 million for the current fiscal year [7] Industry Context - The Medical - Instruments industry, to which Accuray belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Accuray's stock performance [5]